| Jessica M Vanderham, CNP | |
|
513 3rd St Sw, Wagner, SD 57380-9675 | |
| (605) 384-3611 | |
| Not Available |
| Full Name | Jessica M Vanderham |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 7 Years |
| Location | 513 3rd St Sw, Wagner, South Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285143891 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | CP001277 (South Dakota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kernersville Emergency Group, Pllc | 3375885429 | 28 |
| Piedmont Triad Physicians Pllc | 6406197334 | 20 |
| Tanglewood Park Physicians Pllc | 3476895129 | 22 |
News Archive
China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced that it has priced a public offering of 4,600,000 shares of its common stock at $15.00 per share. The shares are being sold under the Company's previously filed shelf registration statement, which was declared effective by the Securities and Exchange Commission on September 9, 2009.
Research by a team at Addenbrooke's Hospital in Cambridge brings hope to children suffering nut allergies of leading a normal life following the success of a pioneering experimental therapy which has allowed the immune system to be 'retrained' to tolerate peanuts and patients with food allergies become desensitised to the food.
T2 Biosystems, a company developing direct detection products enabling superior diagnostics, announced that scientists from the University of Pennsylvania and T2 Biosystems have published a paper in Blood describing novel clot structure biology detected while testing T2 Bio's T2HemoStat-.
Biopharmaceutical company Kiadis Pharma announces that it has successfully completed treatment of the last patient on its ATIR phase I/II clinical trial.
› Verified 1 days ago
| Entity Name | Piedmont Triad Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295206464 PECOS PAC ID: 6406197334 Enrollment ID: O20190403000344 |
News Archive
China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced that it has priced a public offering of 4,600,000 shares of its common stock at $15.00 per share. The shares are being sold under the Company's previously filed shelf registration statement, which was declared effective by the Securities and Exchange Commission on September 9, 2009.
Research by a team at Addenbrooke's Hospital in Cambridge brings hope to children suffering nut allergies of leading a normal life following the success of a pioneering experimental therapy which has allowed the immune system to be 'retrained' to tolerate peanuts and patients with food allergies become desensitised to the food.
T2 Biosystems, a company developing direct detection products enabling superior diagnostics, announced that scientists from the University of Pennsylvania and T2 Biosystems have published a paper in Blood describing novel clot structure biology detected while testing T2 Bio's T2HemoStat-.
Biopharmaceutical company Kiadis Pharma announces that it has successfully completed treatment of the last patient on its ATIR phase I/II clinical trial.
› Verified 1 days ago
| Entity Name | Kernersville Emergency Group, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750852034 PECOS PAC ID: 3375885429 Enrollment ID: O20190422001205 |
News Archive
China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced that it has priced a public offering of 4,600,000 shares of its common stock at $15.00 per share. The shares are being sold under the Company's previously filed shelf registration statement, which was declared effective by the Securities and Exchange Commission on September 9, 2009.
Research by a team at Addenbrooke's Hospital in Cambridge brings hope to children suffering nut allergies of leading a normal life following the success of a pioneering experimental therapy which has allowed the immune system to be 'retrained' to tolerate peanuts and patients with food allergies become desensitised to the food.
T2 Biosystems, a company developing direct detection products enabling superior diagnostics, announced that scientists from the University of Pennsylvania and T2 Biosystems have published a paper in Blood describing novel clot structure biology detected while testing T2 Bio's T2HemoStat-.
Biopharmaceutical company Kiadis Pharma announces that it has successfully completed treatment of the last patient on its ATIR phase I/II clinical trial.
› Verified 1 days ago
| Entity Name | Tanglewood Park Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093286379 PECOS PAC ID: 3476895129 Enrollment ID: O20190429001041 |
News Archive
China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced that it has priced a public offering of 4,600,000 shares of its common stock at $15.00 per share. The shares are being sold under the Company's previously filed shelf registration statement, which was declared effective by the Securities and Exchange Commission on September 9, 2009.
Research by a team at Addenbrooke's Hospital in Cambridge brings hope to children suffering nut allergies of leading a normal life following the success of a pioneering experimental therapy which has allowed the immune system to be 'retrained' to tolerate peanuts and patients with food allergies become desensitised to the food.
T2 Biosystems, a company developing direct detection products enabling superior diagnostics, announced that scientists from the University of Pennsylvania and T2 Biosystems have published a paper in Blood describing novel clot structure biology detected while testing T2 Bio's T2HemoStat-.
Biopharmaceutical company Kiadis Pharma announces that it has successfully completed treatment of the last patient on its ATIR phase I/II clinical trial.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jessica M Vanderham, CNP 513 3rd St Sw, Wagner, SD 57380-9675 Ph: (605) 384-3611 | Jessica M Vanderham, CNP 513 3rd St Sw, Wagner, SD 57380-9675 Ph: (605) 384-3611 |
News Archive
China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced that it has priced a public offering of 4,600,000 shares of its common stock at $15.00 per share. The shares are being sold under the Company's previously filed shelf registration statement, which was declared effective by the Securities and Exchange Commission on September 9, 2009.
Research by a team at Addenbrooke's Hospital in Cambridge brings hope to children suffering nut allergies of leading a normal life following the success of a pioneering experimental therapy which has allowed the immune system to be 'retrained' to tolerate peanuts and patients with food allergies become desensitised to the food.
T2 Biosystems, a company developing direct detection products enabling superior diagnostics, announced that scientists from the University of Pennsylvania and T2 Biosystems have published a paper in Blood describing novel clot structure biology detected while testing T2 Bio's T2HemoStat-.
Biopharmaceutical company Kiadis Pharma announces that it has successfully completed treatment of the last patient on its ATIR phase I/II clinical trial.
› Verified 1 days ago
Lindsey Nedved, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 513 3rd St Sw, Wagner, SD 57380 Phone: 605-384-3611 | |
Carol Lee Stewart, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 513 3rd Street Sw, Wagner, SD 57380 Phone: 605-384-3611 | |
Ashley Marie Ruhaak, CNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 513 3rd St Sw, Wagner, SD 57380 Phone: 605-384-3611 | |
Jazmyn Soukup, DNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 513 3rd St Sw, Wagner, SD 57380 Phone: 605-384-3611 | |
Brooke Lynn Plooster, CNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 513 3rd St Sw, Wagner, SD 57380 Phone: 605-384-3611 Fax: 605-384-5240 | |
Ryan Kocer, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 513 3rd St Sw, Wagner, SD 57380 Phone: 605-384-3611 |